What is the nature of the transaction between Becton Dickinson (BD) and Waters Corporation?

BD is combining its Biosciences and Diagnostic Solutions business with Waters Corporation. This will be structured as a Reverse Morris Trust transaction, which typically involves spinning off a business unit into a new company that then merges with the acquiring company.

What are the expected benefits of this transaction?

While not detailed in this filing, such transactions are generally undertaken to create more focused entities with enhanced strategic flexibility, potentially unlock shareholder value, and drive growth for both the separated business and the remaining parent company. Specific synergies and benefits will be elaborated upon in future communications and filings.

When will more detailed financial information about this transaction be available?

This 8-K filing primarily serves to announce the definitive agreements. More comprehensive financial details, transaction terms, and pro forma information will be disclosed in subsequent SEC filings, including registration statements (Form S-4 for Waters and Form 10 for the new BD entity) and proxy statements, which are expected to be filed in the near future.

What are the key risks associated with this transaction?

The filing outlines several risks, including the potential failure to obtain necessary regulatory approvals, unexpected transaction costs, inability to realize anticipated benefits or synergies, difficulties in integrating the businesses, retention of key personnel, and risks related to the tax treatment of the transaction. Investors are advised to review the full 'Cautionary Statement Regarding Forward-Looking Statements' section for a comprehensive list.

BDX 8-K: Regulation FD — Jul 14, 2025

Summary

Becton, Dickinson and Company (BD) has announced a significant strategic transaction where its Biosciences and Diagnostic Solutions business will be combined with Waters Corporation through a Reverse Morris Trust transaction. This move aims to create a new, independent public company poised for growth in the life sciences sector. While specific financial terms are not detailed in this 8-K filing, the company has published a joint press release, investor presentation, and an overview of the new BD business. Investors should note that this transaction is subject to customary closing conditions, including regulatory approvals and shareholder consent. BD and Waters will host a joint conference call to discuss the transaction, and further detailed information will be provided in subsequent SEC filings, including registration statements and proxy materials.

Key Highlights

1BD is combining its Biosciences and Diagnostic Solutions business with Waters Corporation via a Reverse Morris Trust transaction.
2The transaction will result in the formation of a new, independent public company.
3BD and Waters have issued a joint press release and investor presentation to announce and discuss the transaction.
4A joint conference call and webcast are scheduled for July 14, 2025, to provide further details.
5The transaction is subject to regulatory approvals and other customary closing conditions.
6BD is providing an overview of the 'New BD' business expected to result from the transaction.
7Detailed information regarding the transaction, including financial implications and structure, will be forthcoming in SEC filings like Form S-4 and Form 10.

BECTON DICKINSON & CO 8-K Report, Regulation FD Disclosure (Jul 14, 2025)

Summary

Key Highlights

Frequently Asked Questions